Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
JD HEALTH
06618
5
BIDU-SW
09888
| (FY)Jun 30, 2025 | (FY)Jun 30, 2024 | (FY)Jun 30, 2023 | (FY)Jun 30, 2022 | (FY)Jun 30, 2021 | (FY)Jun 30, 2020 | (FY)Jun 30, 2019 | (FY)Jun 30, 2018 | |
|---|---|---|---|---|---|---|---|---|
| Total revenue | 25.13K | |||||||
| Operating revenue | --25.13K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cost of revenue | 224.89K | |||||||
| Gross profit | -199.77K | |||||||
| Operating expense | 20.69%6.7M | -51.93%5.55M | 2.63%11.54M | 45.42%11.25M | 85.84%7.73M | 12.02%4.16M | 128.10%3.71M | 1.63M |
| Selling and administrative expenses | 72.52%5.12M | -60.49%2.97M | 27.32%7.51M | 94.67%5.9M | 48.51%3.03M | -20.97%2.04M | 111.64%2.58M | --1.22M |
| -Selling and marketing expense | ---- | -34.21%115.5K | -68.75%175.56K | 794.38%561.86K | 50.12%62.82K | -86.19%41.85K | 224.07%302.93K | --93.48K |
| -General and administrative expense | 79.51%5.12M | -61.12%2.85M | 37.44%7.33M | 79.84%5.33M | 48.47%2.97M | -12.29%2M | 102.31%2.28M | --1.13M |
| Research and development costs | -41.00%1.38M | -35.70%2.35M | -29.30%3.65M | 13.27%5.16M | 134.85%4.55M | 97.84%1.94M | 172.97%980.28K | --359.11K |
| Depreciation amortization depletion | -0.94%196.78K | 4.90%198.66K | 86.62%189.38K | -30.80%101.48K | 3.79%146.65K | 116.15%141.29K | 107.28%65.37K | --31.54K |
| -Depreciation and amortization | -0.94%196.78K | 4.90%198.66K | 86.62%189.38K | -30.80%101.48K | 3.79%146.65K | 116.15%141.29K | 107.28%65.37K | --31.54K |
| Other operating expenses | ---- | -80.48%38.82K | 120.75%198.85K | 2,319.53%90.08K | -91.04%3.72K | -53.29%41.55K | 372.28%88.96K | --18.84K |
| Operating profit | -24.29%-6.9M | 51.93%-5.55M | -2.63%-11.54M | -45.42%-11.25M | -85.84%-7.73M | -12.02%-4.16M | -128.10%-3.71M | -1.63M |
| Net non-operating interest income (expenses) | 37.58%67.61K | -78.47%49.14K | 814.36%228.27K | 95.16%24.97K | -66.75%12.79K | -72.73%38.47K | 118.79%141.07K | 64.48K |
| Non-operating interest income | 156.93%134.33K | -77.10%52.28K | 814.36%228.27K | 78.67%24.97K | -69.80%13.97K | -67.20%46.27K | 118.79%141.07K | --64.48K |
| Non-operating interest expense | 2,022.91%66.72K | --3.14K | ---- | ---- | -94.92%396 | --7.8K | ---- | ---- |
| Total other finance cost | ---- | ---- | ---- | ---- | --785 | ---- | ---- | ---- |
| Other net income (expenses) | 320.98%3M | -143.85%-1.36M | 27.54%3.1M | 118.98%2.43M | 1,008.51%1.11M | -90.27%100K | 642.79%1.03M | -189.32K |
| Special income (charges) | ---- | ---3.05M | ---- | ---- | ---- | ---- | ---- | ---- |
| -Less:Impairment of capital assets | ---- | --3.05M | ---- | ---- | ---- | ---- | ---- | ---- |
| Other non-operating income (expenses) | 77.47%3M | -45.41%1.69M | 27.54%3.1M | 118.98%2.43M | 1,008.51%1.11M | -90.27%100K | 642.79%1.03M | ---189.32K |
| Income before tax | 44.15%-3.83M | 16.56%-6.86M | 6.55%-8.22M | -32.99%-8.79M | -64.36%-6.61M | -58.00%-4.02M | -45.21%-2.55M | -1.75M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Earnings from equity interest net of tax | ||||||||
| Net income | 44.15%-3.83M | 16.56%-6.86M | 6.55%-8.22M | -32.99%-8.79M | -64.36%-6.61M | -58.00%-4.02M | -45.21%-2.55M | -1.75M |
| Net income continuous operations | 44.15%-3.83M | 16.56%-6.86M | 6.55%-8.22M | -32.99%-8.79M | -64.36%-6.61M | -58.00%-4.02M | -45.21%-2.55M | ---1.75M |
| Noncontrolling interests | ||||||||
| Net income attributable to the company | 44.15%-3.83M | 16.56%-6.86M | 6.55%-8.22M | -32.99%-8.79M | -64.36%-6.61M | -58.00%-4.02M | -45.21%-2.55M | -1.75M |
| Preferred stock dividends | ||||||||
| Other under preferred stock dividend | ||||||||
| Net income attributable to common stockholders | 44.15%-3.83M | 16.56%-6.86M | 6.55%-8.22M | -32.99%-8.79M | -64.36%-6.61M | -58.00%-4.02M | -45.21%-2.55M | -1.75M |
| Diluted earnings per share | ||||||||
| Basic earnings per share | ||||||||
| Dividend per share | ||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |